---
title: "Betahistine - Meniere Disease"
sidebar: mydoc_sidebar
permalink: db06698-mesh-d008575-1.html
toc: false 
---


Path ID: `DB06698_MESH_D008575_1`
{% include image.html url="images/db06698-mesh-d008575-1.png" file="db06698-mesh-d008575-1.png" alt="db06698-mesh-d008575-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D001621 | Betahistine | Drug |
| UniProt:P35367 | Histamine H1 receptor | Protein |
| MESH:D006632 | Histamine | ChemicalSubstance |
| GO:0042311 | Vasodilation | BiologicalProcess |
| GO:0043117 | Positive regulation of vascular permeability | BiologicalProcess |
| UniProt:Q9Y5N1 | Histamine H3 receptor | Protein |
| MESH:D008575 | Meniere Disease | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Betahistine | INCREASES ACTIVITY OF | Histamine H1 Receptor |
| Histamine H1 Receptor | POSITIVELY CORRELATED WITH | Histamine |
| Histamine | CONTRIBUTES TO | Vasodilation |
| Histamine | CONTRIBUTES TO | Positive Regulation Of Vascular Permeability |
| Betahistine | DECREASES ACTIVITY OF | Histamine H3 Receptor |
| Histamine H3 Receptor | DECREASES ABUNDANCE OF | Histamine |
| Vasodilation | TREATS | Meniere Disease |
| Positive Regulation Of Vascular Permeability | TREATS | Meniere Disease |
|---------|-----------|---------|

Comment: Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

Reference: 
  - [https://en.wikipedia.org/wiki/Histamine_H3_receptor](https://en.wikipedia.org/wiki/Histamine_H3_receptor)
  - [https://go.drugbank.com/drugs/DB06698#BE0000442](https://go.drugbank.com/drugs/DB06698#BE0000442)
